Aktuellt
SENASTE
Redeye retains its positive view on Transtema following its Q3 2022 report revealed earlier today, where both sales and EBITA clearly beat our expectations with strong organic growth. Consequently, we will likely make forecast adjustments slightly affect our valuation.
LÄS MER
